Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-Techne?Launches Simple?Plex?Ultra-Sensitive?Assays on Ella?Platform to Enable?Femtogram-Level?Detection of Neurological Biomarkers
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire
Bold Ventures Provides Update on Burchell Drilling Progress and Announces PDAC Participation at Booth #2610
